Journal Mobile Options
Table of Contents
Vol. 12, No. 5, 2005
Issue release date: September 2005
Neuroimmunomodulation 2005;12:255–269
(DOI:10.1159/000087104)

Cytokine Dysregulation, Inflammation and Well-Being

Elenkov I.J. · Iezzoni D.G. · Daly A. · Harris A.G. · Chrousos G.P.
aDivision of Rheumatology, Immunology and Allergy, Georgetown University Medical Center, Washington, D.C., bIntegrated Therapeutics Group, Inc., a subsidiary of Schering-Plough Co., Kenilworth, N.J., and cNational Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Md., USA; dSan Raffaele Research Center, Rome, Italy; eUniversity of Liege, Liege, Belgium

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Cytokines mediate and control immune and inflammatory responses. Complex interactions exist between cytokines, inflammation and the adaptive responses in maintaining homeostasis, health, and well-being. Like the stress response, the inflammatory reaction is crucial for survival and is meant to be tailored to the stimulus and time. A full-fledged systemic inflammatory reaction results in stimulation of four major programs: the acute-phase reaction, the sickness syndrome, the pain program, and the stress response, mediated by the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. Common human diseases such as atopy/allergy, autoimmunity, chronic infections and sepsis are characterized by a dysregulation of the pro- versus anti-inflammatory and T helper (Th)1versus Th2 cytokine balance. Recent evidence also indicates the involvement of pro-inflammatory cytokines in the pathogenesis of atherosclerosis and major depression, and conditions such as visceral-type obesity, metabolic syndrome and sleep disturbances. During inflammation, the activation of the stress system, through induction of a Th2 shift, protects the organism from systemic ‘overshooting’ with Th1/pro-inflammatory cytokines. Under certain conditions, however, stress hormones may actually facilitate inflammation through induction of interleukin (IL)-1, IL-6, IL-8, IL-18, tumor necrosis factor-α and C-reactive protein production and through activation of the corticotropin-releasing hormone/substance P-histamine axis. Thus, a dysfunctional neuroendocrine-immune interface associated with abnormalities of the ‘systemic anti-inflammatory feedback’ and/or ‘hyperactivity’ of the local pro-inflammatory factors may play a role in the pathogenesis of atopic/allergic and autoimmune diseases, obesity, depression, and atherosclerosis. These abnormalities and the failure of the adaptive systems to resolve inflammation affect the well-being of the individual, including behavioral parameters, quality of life and sleep, as well as indices of metabolic and cardiovascular health. These hypotheses require further investigation, but the answers should provide critical insights into mechanisms underlying a variety of common human immune-related diseases.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Mosmann TR, Sad S: The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138–146.
  2. Fearon DT, Locksley RM: The instructive role of innate immunity in the acquired immune response. Science 1996;272:50–53.
  3. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133–146.
  4. Humbert M, Menz G, Ying S, Corrigan CJ, Robinson DS, Durham SR, et al: The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: More similarities than differences. Immunol Today 1999;20:528–533.
  5. Wills-Karp M: IL-12/IL-13 axis in allergic asthma. J Allergy Clin Immunol 2001;107:9–18.
  6. Prussin C, Metcalfe DD: 4. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2003;111:S486–S494.
  7. Taylor ML, Metcalfe DD: Mast cells in allergy and host defense. Allergy Asthma Proc 2001;22:115–119.
  8. Metcalfe DD, Baram D, Mekori YA: Mast cells. Physiol Rev 1997;77:1033–1079.
  9. Ricca V, Landi M, Ferrero P, Bairo A, Tazzer C, Canonica GW, et al: Minimal persistent inflammation is also present in patients with seasonal allergic rhinitis. J Allergy Clin Immunol 2000;105:54–57.
  10. Ciprandi G, Buscaglia S, Pesce G, Pronzato C, Ricca V, Parmiani S, et al: Minimal persistent inflammation is present at mucosal level in patients with asymptomatic rhinitis and mite allergy. J Allergy Clin Immunol 1995;96:971–979.
  11. Johnston SL, Pattemore PK, Sanderson G, Smith S, Campbell MJ, Josephs LK, et al: The relationship between upper respiratory infections and hospital admissions for asthma: A time-trend analysis. Am J Respir Crit Care Med 1996;154:654–660.
  12. Naseer T, Minshall EM, Leung DY, Laberge S, Ernst P, Martin RJ, et al: Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy. Am J Respir Crit Care Med 1997;155:845–851.
  13. Segal BM, Dwyer BK, Shevach EM: An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med 1998;187:537–546.
  14. Bouma G, Strober W: The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521–533.
  15. Strober W, Fuss I, Kitani A: Regulation of experimental mucosal inflammation. Acta Odontol Scand 2001;59:244–247.
  16. Fuss IJ, Marth T, Neurath MF, Pearlstein GR, Jain A, Strober W: Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology 1999;117:1078–1088.
  17. Kronfol Z, Remick DG: Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry 2000;157:683–694.
  18. Corcos M, Guilbaud O, Hjalmarsson L, Chambry J, Jeammet P: Cytokines and depression: an analogic approach. Biomed Pharmacother 2002;56:105–110.
  19. Wichers M, Maes M: The psychoneuroimmuno-pathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 2002;5:375–388.
  20. Greaves DR, Channon KM: Inflammation and immune responses in atherosclerosis. Trends Immunol 2002;23:535–541.
  21. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138–150.
  22. Baeuerle PA, Baltimore D: Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor. Cell 1988;53:211–217.
  23. Meduri GU, Tolley EA, Chrousos GP, Stentz F: Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. Am J Respir Crit Care Med 2002;165:983–991.
  24. Stentz F, Tolley E, Chrousos G, Meduri GU: Mechanisms of NF-κB and glucocorticoid receptors in activation and regulation of systemic inflammation in ARDS. Am J Respir Crit Care Med 2001;163:A450.
  25. Elenkov IJ, Chrousos GP: Stress hormones, Th1/Th2 patterns, pro/anti-inflammatory cytokines and susceptibility to disease. Trends Endocrinol Metab 1999;10:359–368.
  26. Elenkov IJ, Papanicolaou DA, Wilder RL, Chrousos GP: Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. Proc Assoc Am Physicians 1996;108:374–381.
  27. Panina-Bordignon P, Mazzeo D, Lucia PD, D’Ambrosio D, Lang R, Fabbri L, et al: Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 1997;100:1513–1519.
  28. Hasko G, Szabo C, Nemeth ZH, Salzman AL, Vizi ES: Stimulation of beta-adrenoceptors inhibits endotoxin-induced IL-12 production in normal and IL-10 deficient mice. J Neuroimmunol 1998;88:57–61.
  29. Blotta MH, DeKruyff RH, Umetsu DT: Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. J Immunol 1997;158:5589–5595.
  30. DeKruyff RH, Fang Y, Umetsu DT: Corticosteroids enhance the capacity of macrophages to induce Th2 cytokine synthesis in CD4+ lymphocytes by inhibiting IL-12 production. J Immunol 1998;160:2231–2237.
  31. Wu CY, Wang K, McDyer JF, Seder RA: Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J Immunol 1998;161:2723–2730.
  32. Ramierz F, Fowell DJ, Puklavec M, Simmonds S, Mason D: Glucocorticoids promote a TH2 cytokine response by CD4+ T cells in vitro. J Immunol 1996;156:2406–2412.
  33. van der Poll T, Barber AE, Coyle SM, Lowry SF: Hypercortisolemia increases plasma interleukin-10 concentrations during human endotoxemia – a clinical research center study. J Clin Endocrinol Metab 1996;81:3604–3606.
  34. Hetier E, Ayala J, Bousseau A, Prochiantz A: Modulation of interleukin-1 and tumor necrosis factor expression by beta-adrenergic agonists in mouse ameboid microglial cells. Exp Brain Res 1991;86:407–413.
  35. Severn A, Rapson NT, Hunter CA, Liew FY: Regulation of tumor necrosis factor production by adrenaline and β-adrenergic agonists. J Immunol 1992;148:3441–3445.
  36. Nakamura A, Johns EJ, Imaizumi A, Abe T, Kohsaka T: Regulation of tumour necrosis factor and interleukin-6 gene transcription by beta2-adrenoceptor in the rat astrocytes. J Neuroimmunol 1998;88:144–153.
  37. Koff WC, Fann AV, Dunegan MA, Lachman LB: Catecholamine-induced suppression of interleukin-1 production. Lymphokine Res 1986;5:239–247.
  38. van der Poll T, Lowry SF: Epinephrine inhibits endotoxin-induced IL-1 beta production: roles of tumor necrosis factor-alpha and IL-10. Am J Physiol 1997;273:R1885–R1890.
  39. Sanders VM, Baker RA, Ramer-Quinn DS, Kasprowicz DJ, Fuchs BA, Street NE: Differential expression of the beta2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help. J Immunol 1997;158:4200–4210.
  40. Borger P, Hoekstra Y, Esselink MT, Postma DS, Zaagsma J, Vellenga E, et al: Beta-adrenoceptor-mediated inhibition of IFN-gamma, IL-3, and GM-CSF mRNA accumulation in activated human T lymphocytes is solely mediated by the beta2-adrenoceptor subtype. Am J Respir Cell Mol Biol 1998;19:400–407.
  41. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF: Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 1996;97:713–719.
  42. Norris JG, Benveniste EN: Interleukin-6 production by astrocytes: induction by the neurotransmitter norepinephrine. J Neuroimmunol 1993;45:137–145.
  43. Maimone D, Cioni C, Rosa S, Macchia G, Aloisi F, Annunziata P: Norepinephrine and vasoactive intestinal peptide induce IL-6 secretion by astrocytes: synergism with IL-1 beta and TNF alpha. J Neuroimmunol 1993;47:73–81.
  44. Hasko G, Kuhel DG, Salzman AL, Szabo C: ATP suppression of interleukin-12 and tumour necrosis factor-alpha release from macrophages. Br J Pharmacol 2000;129:909–914.
  45. Wilkin F, Stordeur P, Goldman M, Boeynaems JM, Robaye B: Extracellular adenine nucleotides modulate cytokine production by human monocyte-derived dendritic cells: dual effect on IL-12 and stimulation of IL-10. Eur J Immunol 2002;32:2409–2417.
  46. la Sala A, Ferrari D, Corinti S, Cavani A, Di Virgilio F, Girolomoni G: Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses. J Immunol 2001;166:1611–1617.
  47. Perregaux DG, McNiff P, Laliberte R, Conklyn M, Gabel CA: ATP acts as an agonist to promote stimulus-induced secretion of IL-1 beta and IL-18 in human blood. J Immunol 2000;165:4615–4623.
  48. Chakfe Y, Seguin R, Antel JP, Morissette C, Malo D, Henderson D, et al: ADP and AMP induce interleukin-1beta release from microglial cells through activation of ATP-primed P2X7 receptor channels. J Neurosci 2002;22:3061–3069.
  49. Cronstein BN, Naime D, Ostad E: The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993;92:2675–2682.
  50. Cronstein BN, Rosenstein ED, Kramer SB, Weissmann G, Hirschhorn R: Adenosine; a physiologic modulator of superoxide anion generation by human neutrophils. Adenosine acts via an A2 receptor on human neutrophils. J Immunol 1985;135:1366–1371.
  51. Lappin D, Riches DW, Damerau B, Whaley K: Cyclic nucleotides and their relationship to complement-component-C2 synthesis by human monocytes. Biochem J 1984;222:477–486.
  52. Link AA, Kino T, Worth JA, McGuire JL, Crane ML, Chrousos GP, et al: Ligand-activation of the adenosine A2a receptors inhibits IL-12 production by human monocytes. J Immunol 2000;164:436–442.
  53. Prabhakar U, Brooks DP, Lipshlitz D, Esser KM: Inhibition of LPS-induced TNF alpha production in human monocytes by adenosine (A2) receptor selective agonists. Int J Immunopharmacol 1995;17:221–224.
  54. Le Moine O, Stordeur P, Schandene L, Marchant A, de Groote D, Goldman M, et al: Adenosine enhances IL-10 secretion by human monocytes. J Immunol 1996;156:4408–4414.
  55. Hasko G, Szabo C, Nemeth ZH, Kvetan V, Pastores SM, Vizi ES: Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 1996;157:4634–4640.
  56. Falus A, Meretey K: Histamine: an early messenger in inflammatory and immune reactions. Immunol Today 1992;13:154–156.
  57. Vannier E, Miller LC, Dinarello CA: Histamine suppresses gene expression and synthesis of tumor necrosis factor alpha via histamine H2 receptors. J Exp Med 1991;174:281–284.
  58. Vannier E, Dinarello CA: Histamine enhances interleukin (IL)-1-induced IL-6 gene expression and protein synthesis via H2 receptors in peripheral blood mononuclear cells. J Biol Chem 1994;269:9952–9956.
  59. Elenkov IJ, Webster E, Papanicolaou DA, Fleisher TA, Chrousos GP, Wilder RL: Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors. J Immunol 1998;161:2586–2593.
  60. Idzko M, la Sala A, Ferrari D, Panther E, Herouy Y, Dichmann S, et al: Expression and function of histamine receptors in human monocyte-derived dendritic cells. J Allergy Clin Immunol 2002;109:839 –846.

    External Resources

  61. Lagier B, Lebel B, Bousquet J, Pene J: Different modulation by histamine of IL-4 and interferon-gamma (IFN-γ) release according to the phenotype of human Th0, Th1 and Th2 clones. Clin Exp Immunol 1997;108:545–551.
  62. Lotz M, Vaughan JH, Carson DA: Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science 1988;241:1218–1221.
  63. Kincy-Cain T, Bost KL: Substance P-induced IL-12 production by murine macrophages. J Immunol 1997;158:2334–2339.
  64. Ho WZ, Stavropoulos G, Lai JP, Hu BF, Magafa V, Anagnostides S, et al: Substance P C-terminal octapeptide analogues augment tumor necrosis factor-alpha release by human blood monocytes and macrophages. J Neuroimmunol 1998;82:126–132.
  65. Fox FE, Kubin M, Cassin M, Niu Z, Hosoi J, Torii H, et al: Calcitonin gene-related peptide inhibits proliferation and antigen presentation by human peripheral blood mononuclear cells: effects on B7, interleukin 10, and interleukin 12. J Invest Dermatol 1997;108:43–48.
  66. Liu J, Chen M, Wang X: Calcitonin gene-related peptide inhibits lipopolysaccharide-induced interleukin-12 release from mouse peritoneal macrophages, mediated by the cAMP pathway. Immunology 2000;101:61–67.
  67. Ganea D, Delgado M: Inhibitory neuropeptide receptors on macrophages. Microbes Infect 2001;3:141–147.
  68. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al: Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000;405:458–462.
  69. Tracey KJ: The inflammatory reflex. Nature 2002;420:853–859.
  70. Bentley AM, Hamid Q, Robinson DS, Schotman E, Meng Q, Assoufi B, et al: Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med 1996;153:551–556.
  71. Bradding P, Feather IH, Wilson S, Holgate ST, Howarth PH: Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid. Am J Respir Crit Care Med 1995;151:1900–1906.
  72. Batuman OA, Ferrero A, Cupp C, Jimenez SA, Khalili K: Differential regulation of transforming growth factor beta-1 gene expression by glucocorticoids in human T and glial cells. J Immunol 1995;155:4397–4405.
  73. Broug-Holub E, Kraal G: Dose- and time-dependent activation of rat alveolar macrophages by glucocorticoids. Clin Exp Immunol 1996;104:332–336.
  74. Spengler RN, Allen RM, Remick DG, Strieter RM, Kunkel SL: Stimulation of α-adrenergic receptor augments the production of macrophage-derived tumor necrosis factor. J Immunol 1990;145:1430–1434.
  75. Le Tulzo Y, Shenkar R, Kaneko D, Moine P, Fantuzzi G, Dinarello CA, et al: Hemorrhage increases cytokine expression in lung mononuclear cells in mice: involvement of catecholamines in nuclear factor-κB regulation and cytokine expression. J Clin Invest 1997;99:1516–1524.
  76. Broug-Holub E, Persoons JH, Schornagel K, Mastbergen SC, Kraal G: Effects of stress on alveolar macrophages: a role for the sympathetic nervous system. Am J Respir Cell Mol Biol 1998;19:842–848.
  77. Kavelaars A, van de Pol M, Zijlstra J, Heijnen CJ: Beta 2-adrenergic activation enhances interleukin-8 production by human monocytes. J Neuroimmunol 1997;77:211–216.
  78. Linden A: Increased interleukin-8 release by beta-adrenoceptor activation in human transformed bronchial epithelial cells. Br J Pharmacol 1996;119:402–406.
  79. Engstad CS, Lund T, Osterud B: Epinephrine promotes IL-8 production in human leukocytes via an effect on platelets. Thromb Haemost 1999;81:139–145.
  80. Kaplanski G, Porat R, Aiura K, Erban JK, Gelfand JA, Dinarello CA: Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event. Blood 1993;81:2492–2495.
  81. Mohamed-Ali V, Flower L, Sethi J, Hotamisligil G, Gray R, Humphries SE, et al: Beta-adrenergic regulation of IL-6 release from adipose tissue: in vivo and in vitro studies. J Clin Endocrinol Metab 2001;86:5864–5869.
  82. Vicennati V, Vottero A, Friedman C, Papanicolaou DA: Hormonal regulation of interleukin-6 production in human adipocytes. Int J Obes Relat Metab Disord 2002;26:905–911.
  83. Baumann H, Gauldie J: The acute phase response. Immunol Today 1994;15:74–80.
  84. Li Y, Chi L, Stechschulte DJ, Dileepan KN: Histamine-induced production of interleukin-6 and interleukin-8 by human coronary artery endothelial cells is enhanced by endotoxin and tumor necrosis factor-alpha. Microvasc Res 2001;61:253–262.
  85. Murray DR, Prabhu SD, Chandrasekar B: Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 2000;101:2338–2341.
  86. Karalis K, Sano H, Redwine J, Listwak S, Wilder RL, Chrousos GP: Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 1991;254:421–423.
  87. Elenkov IJ, Webster EL, Torpy DJ, Chrousos GP: Stress, corticotropin-releasing hormone, glucocorticoids, and the immune/inflammatory response: acute and chronic effects. Ann NY Acad Sci 1999;876:1–11.
  88. Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E, et al: Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 1998;139:403–413.
  89. Foreman JC: Substance P and calcitonin gene-related peptide: effects on mast cells and in human skin. Int Arch Allergy Appl Immunol 1987;82:366–371.
  90. Church MK, Lowman MA, Robinson C, Holgate ST, Benyon RC: Interaction of neuropeptides with human mast cells. Int Arch Allergy Appl Immunol 1989;88:70–78.
  91. Theoharides TC, Spanos C, Pang X, Alferes L, Ligris K, Letourneau R, et al: Stress-induced intracranial mast cell degranulation: a corticotropin-releasing hormone-mediated effect. Endocrinology 1995;136:5745–5750.
  92. Chrousos GP: The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation (see comments). N Engl J Med 1995;332:1351–1362.
  93. Chrousos GP: Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. Ann NY Acad Sci 1998;851:311–335.
  94. Clauw DJ, Chrousos GP: Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 1997;4:134–153.
  95. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP: The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998;128:127–137.
  96. Crofford LJ, Kalogeras KT, Mastorakos G, Magiakou MA, Wells J, Kanik KS, et al: Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab 1997;82:1279–1283.
  97. Vgontzas AN, Papanicolaou DA, Bixler EO, Lotsikas A, Zachman K, Kales A, et al: Circadian interleukin-6 secretion and quantity and depth of sleep. J Clin Endocrinol Metab 1999;84:2603–2607.
  98. Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin HM, et al: Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 2000;85:1151–1158.
  99. Vgontzas AN, Zoumakis M, Papanicolaou DA, Bixler EO, Prolo P, Lin HM, et al: Chronic insomnia is associated with a shift of interleukin-6 and tumor necrosis factor secretion from nighttime to daytime. Metabolism 2002;51:887–892.
  100. Vgontzas AN, Papanicolaou DA, Bixler EO, Kales A, Tyson K, Chrousos GP: Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 1997;82:1313–1316.
  101. Marshall GD Jr, Agarwal SK: Stress, immune regulation, and immunity: applications for asthma. Allergy Asthma Proc 2000;21:241–246.
  102. von Hertzen LC: Maternal stress and T-cell differentiation of the developing immune system: possible implications for the development of asthma and atopy. J Allergy Clin Immunol 2002;109:923–928.
  103. Barnes P, FitzGerald G, Brown M, Dollery C: Nocturnal asthma and changes in circulating epinephrine, histamine, and cortisol. N Engl J Med 1980;303:263–267.
  104. Panina-Bordignon P, Mazzeo D, Lucia PD, D’Ambrosio D, Lang R, Fabbri L, et al: β2-Agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 1997;100:1513–1519.
  105. Zieg G, Lack G, Harbeck RJ, Gelfand EW, Leung DY: In vivo effects of glucocorticoids on IgE production (see comments). J Allergy Clin Immunol 1994;94:222–230.
  106. Coqueret O, Lagente V, Frere CP, Braquet P, Mencia-Huerta JM: Regulation of IgE production by beta 2-adrenoceptor agonists. Ann NY Acad Sci 1994;725:44–49.
  107. Sternberg EM: Neuroendocrine regulation of autoimmune/inflammatory disease. J Endocrinol 2001;169:429–435.
  108. Elenkov IJ, Chrousos GP: Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann NY Acad Sci 2002;966:290–303.
  109. Sternberg EM, Young WS, Bernardini R, Calogero AE, Chrousos GP, Gold PW, et al: A central nervous system defect in biosynthesis of corticotropin-releasing hormone is associated with susceptibility to streptococcal cell wall-induced arthritis in Lewis rats. Proc Natl Acad Sci USA 1989;86:4771–4775.
  110. Sternberg EM, Hill JM, Chrousos GP, Kamilaris T, Listwak SJ, Gold PW, et al: Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats. Proc Natl Acad Sci USA 1989;86:2374–2378.
  111. Wilder RL: Neuroendocrine-immune system interactions and autoimmunity. Annu Rev Immunol 1995;13:307–338.
  112. Wilder RL, Elenkov IJ: Hormonal regulation of tumor necrosis factor-alpha, interleukin-12 and interleukin-10 production by activated macrophages. A disease-modifying mechanism in rheumatoid arthritis and systemic lupus erythematosus? Ann NY Acad Sci 1999;876:14–31.
  113. Straub RH, Cutolo M: Involvement of the hypothalamic-pituitary-adrenal/gonadal axis and the peripheral nervous system in rheumatoid arthritis: viewpoint based on a systemic pathogenetic role. Arthritis Rheum 2001;44:493–507.
  114. Karaszewski JW, Reder AT, Maselli R, Brown M, Arnason BG: Sympathetic skin responses are decreased and lymphocyte beta-adrenergic receptors are increased in progressive multiple sclerosis. Ann Neurol 1990;27:366–372.
  115. Arnason BG, Brown M, Maselli R, Karaszewski J, Reder A: Blood lymphocyte beta-adrenergic receptors in multiple sclerosis. Ann NY Acad Sci 1988;540:585–588.
  116. Karaszewski JW, Reder AT, Anlar B, Arnason GW: Increased high affinity beta-adrenergic receptor densities and cyclic AMP responses of CD8 cells in multiple sclerosis. J Neuroimmunol 1993;43:1–7.
  117. Arnason BG, Noronha AB, Reder AT: Immunoregulation in rapidly progressive multiple sclerosis. Ann NY Acad Sci 1988;540:4–12.
  118. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES: The sympathetic nerve – an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 2000;52:595–638.
  119. Miller LE, Justen HP, Scholmerich J, Straub RH: The loss of sympathetic nerve fibers in the synovial tissue of patients with rheumatoid arthritis is accompanied by increased norepinephrine release from synovial macrophages. FASEB J 2000;14:2097–2107.
  120. Elenkov IJ, Wilder RL, Bakalov VK, Link AA, Dimitrov MA, Fisher S, et al: IL-12, TNF-alpha, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times. J Clin Endocrinol Metab 2001;86:4933–4938.
  121. Wong ML, Kling MA, Munson PJ, Listwak S, Licinio J, Prolo P, et al: Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci USA 2000;97:325–330.
  122. Gold PW, Chrousos GP: The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences. Proc Assoc Am Physicians 1999;111:22–34.
  123. Gold PW, Chrousos GP: Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs. low CRH/NE states. Mol Psychiatry 2002;7:254–275.
  124. Jarek MJ, Legare EJ, McDermott MT, Merenich JA, Kollef MH: Endocrine profiles for outcome prediction from the intensive care unit. Crit Care Med 1993;21:543–550.
  125. Rothwell PM, Lawler PG: Prediction of outcome in intensive care patients using endocrine parameters (see comments). Crit Care Med 1995;23:78–83.
  126. Munford RS, Tracey KJ: Is severe sepsis a neuroendocrine disease? Mol Med 2002;8:437–442.
  127. O’Sullivan ST, Lederer JA, Horgan AF, Chin DH, Mannick JA, Rodrick ML: Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection (see comments). Ann Surg 1995;222:482–490.
  128. Brune IB, Wilke W, Hensler T, Holzmann B, Siewert JR: Downregulation of T helper type 1 immune response and altered pro-inflammatory and anti-inflammatory T cell cytokine balance following conventional but not laparoscopic surgery. Am J Surg 1999;177:55–60.
  129. Woiciechowsky C, Asadullah K, Nestler D, Eberhardt B, Platzer C, Schoning B, et al: Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury (in process citation). Nat Med 1998;4:808–813.
  130. Franchimont D, Kino T, Galon J, Meduri GU, Chrousos G: Glucocorticoids and inflammation revisited: the state of the art. NIH Clinical Staff Conference. Neuroimmunomodulation 2003;10:247–260.
  131. Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C. Meta-analysis: the effect of steroids on survival and shock during sepsis depends on the dose. Ann Intern Med 2004;141:47–56.
  132. Meduri GU, Chrousos GP: Duration of glucocorticoid treatment and outcome in sepsis: is the right drug used the wrong way? Chest 1998;114:355–360.
  133. Meduri GU, Kanangat S: Glucocorticoid treatment of sepsis and acute respiratory distress syndrome: time for a critical reappraisal. Crit Care Med 1998;26:630–633.
  134. Meduri GU: New rationale for glucocorticoid treatment in septic shock. J Chemother 1999;11:541–550.
  135. Altare F, Durandy A, Lammas D, Emile JF, Lamhamedi S, Le Deist F, et al: Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998;280:1432–1435.
  136. Lerner BH: Can stress cause disease? Revisiting the tuberculosis research of Thomas Holmes, 1949–1961. Ann Intern Med 1996;124:673–680.
  137. Levenstein S, Ackerman S, Kiecolt-Glaser JK, Dubois A: Stress and peptic ulcer disease. JAMA 1999;281:10–11.
  138. Cohen S, Tyrrell DA, Smith AP: Psychological stress and susceptibility to the common cold (see comments). N Engl J Med 1991;325:606–612.
  139. Cole SW, Korin YD, Fahey JL, Zack JA: Norepinephrine accelerates HIV replication via protein kinase A-dependent effects on cytokine production. J Immunol 1998;161:610–616.
  140. Cole SW, Naliboff BD, Kemeny ME, Griswold MP, Fahey JL, Zack JA: Impaired response to HAART in HIV-infected individuals with high autonomic nervous system activity. Proc Natl Acad Sci USA 2001;98:12695–12700.
  141. Kino T, Gragerov A, Kopp JB, Stauber RH, Pavlakis GN, Chrousos GP: The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor (in process citation). J Exp Med 1999;189:51–62.
  142. Mirani M, Elenkov I, Volpi S, Hiroi N, Chrousos GP, Kino T: HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection. J Immunol 2002;169:6361–6368.
  143. Rook GA, Lightman SL, Heijnen CJ: Can nerve damage disrupt neuroendocrine immune homeostasis? Leprosy as a case in point. Trends Immunol 2002;23:18–22.
  144. Black PH: Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun 2002;16:622–653.
  145. Black PH, Garbutt LD: Stress, inflammation and cardiovascular disease. J Psychosom Res 2002;52:1–23.
  146. Elenkov IJ: Neuroendocrine effects on immune system; in DeGroot L, Chrousos GP (eds): www.endotext.com/ (online Endocrine Source). 2003.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50